Nyxoah Submits FDA Application To Expand Genio Indication To Complete Concentric Collapse Patients; Pivotal Data Show 74.3% Median Reduction In Apnea Events
Share
Why It Matters
Nyxoah asked the FDA to let its sleep apnea device help more patients. The device showed it cuts breathing problems by about three quarters.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.